Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 3/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.33 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | BAD | Q92934 | 2/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RGS12 | O14924 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12446382 | 0.72 | NQO2 (0.46) | NQO2CYP19A1PTGS2TXNRD1TXNRD3 | |
| SCHEMBL4596292 | 0.66 | ABCG2 (0.40) | NQO2CYP19A1PTGS2TXNRD1TXNRD3 | |
| SCHEMBL8334782 | 0.65 | NQO2 (0.46) | NQO2CYP19A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL12023132 | 0.65 | AOC3 (0.53) | TXNRD1TXNRD3TXNRD2AOC3ABCG2 | |
| SCHEMBL2195125 | 0.65 | NQO2 (0.42) | NQO2CYP19A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL16366159 | 0.63 | DRD2 (0.42) | NQO2CYP19A1PTGS2DRD2DRD1 | |
| SCHEMBL881447 | 0.63 | NQO2 (0.45) | NQO2CYP19A1PTGS2TXNRD1TXNRD3 | |
| SCHEMBL16072579 | 0.63 | NQO2 (0.38) | NQO2CYP19A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL583885 | 0.62 | PTGS2 (0.38) | NQO2CYP19A1PTGS2TXNRD1TXNRD3 | |
| SCHEMBL25166052 | 0.62 | NQO2 (0.44) | NQO2CYP19A1TXNRD1TXNRD3TXNRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051042-A1 | METHODS FOR FORMING SATURATED (HETERO)CYCLIC BORYLATED HYDROCARBONS AND RELATED COMPOUNDS | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| EP-1419815-B1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO PERFUMERY CO LTD (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-7078568-B2 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-07-18 | — | — | US | disclosed |
| US-6987202-B2 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-01-17 | — | — | US | disclosed |
| US-20050288531-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | SHIMIZU HIDEO | 2005-12-29 | — | — | US | disclosed |
| EP-1419815-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | Takasago International Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-20040092388-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051042-A1 | METHODS FOR FORMING SATURATED (HETERO)CYCLIC BORYLATED HYDROCARBONS AND RELATED COMPOUNDS | BRS3, CBR3, C9 | NQO2 3252/4885CYP19A1 799/4885PTGS2 3301/4885 |
| US-20050288531-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | PHOSPHO1, PRMT1, PRMT9 | NQO2 4268/4885CYP19A1 2929/4885PTGS2 2895/4885 |
| US-20040092388-A1 | Phosphine compounds, transition metal complexes with the compounds contained as ligands therein, and asymmetric synthesis catalysts containing the complexes | PHOSPHO1, INPP5B, PRMT1 | NQO2 4614/4885CYP19A1 3607/4885PTGS2 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.